Autolus Therapeutics plc (AUTL)

NASDAQ: AUTL · Real-Time Price · USD

1.440

+0.020 (1.41%)

At close: Jan 15, 2026, 4:00 PM EST

1.450

+0.010 (0.67%)

Pre-market: Jan 16, 2026, 8:45 AM EST

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2014 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2014 - 2019
Chimeric Antigen Receptors T Cell Therapies	10.12M	Log In	Log In	Log In	Log In	Upgrade
Chimeric Antigen Receptors T Cell Therapies Growth	496.00%	Log In	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2014 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2014 - 2019
Europe	10.12M	Log In	Log In	Log In	Log In	Upgrade
United States	-	Log In	Log In	Log In	Log In	Upgrade
United Kingdom	-	Log In	Log In	Log In	Log In	Upgrade
United Kingdom, Europe and United States	-	Log In	Log In	Log In	Log In	Upgrade
United Kingdom, Europe and United States Growth	-	Log In	Log In	Log In	Log In	Upgrade